Perucca, Emilio http://orcid.org/0000-0001-8703-223X
Bialer, Meir http://orcid.org/0000-0003-2046-4171
White, H. Steve http://orcid.org/0000-0003-4550-4408
Funding for this research was provided by:
University of Melbourne
Article History
Accepted: 6 July 2023
First Online: 21 August 2023
Declarations
:
: Open Access funding enabled and organized by CAUL and its Member Institutions. The preparation of this article was not supported by any funding source.
: Emilio Perucca received speaker fees or fees from consulting or participation in advisory boards/data safety monitoring boards from Angelini, Arvelle, Biopas, Eisai, GW Pharma, Janssen, PMI Life Sciences, Sanofi group of companies, Shackelford Pharma, SKL Life Science, Sun Pharma, Takeda, UCB Pharma, Xenon Pharma and Zogenix, and royalties from Wiley, Elsevier and Wolters Kluwers, all outside the submitted work. Meir Bialer received speaker’s or consultancy fees from Boehringer Ingelheim, Clexio Therapeutics, Guidepoint, Pharma2B, Shackelford Pharma and US WorldMeds. H. Steve White has received grant funding from UCB Pharma and Eisai Pharmaceuticals, Neurelis, Inc. and consultant fees from GW Pharmaceuticals, Neurelis, Inc., Takeda Pharmaceuticals, SK Life Sciences and Jazz Pharmaceuticals and speaker honoraria from SK Pharmaceuticals, Takeda Pharmaceuticals and UCB Pharma.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: This article is an invited review. All authors contributed to the literature search. EP produced the initial draft of the Summary, Key Points, Introduction, Sect.InternalRef removedand Conclusions. HSW produced the initiat draft of Sect.InternalRef removed. MB produced the initial draft of Sect. 4.2. All authors participated equally in the finalisation of the manuscript and they all met ICMJE criteria for authorship. All authors have read and approved the final submitted manuscript, and agree to be accountable for the work.